Antiviral drugs for HBV liver disease

Expert Opinion on Biological Therapy

Volumn 11, Issue 3, 2011, Pages 285-300

  Viganò, Mauro ^a   Lampertico, Pietro ^b  

^a San Giuseppe Hospital   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

antiviral treatment; chronic hepatitis B; entecavir; HBV; pegylated interferon; tenofovir

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EMTRICITABINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; VIRUS DNA;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTIVIRAL SUSCEPTIBILITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL INFECTION; COUGHING; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; CROSS RESISTANCE; CYTOPENIA; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; FATIGUE; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; INJECTION SITE REACTION; KIDNEY FAILURE; LACTIC ACIDOSIS; LIVER BIOPSY; LIVER CIRRHOSIS; MYALGIA; NEUTROPENIA; NONHUMAN; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEROCONVERSION; SIDE EFFECT; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HEPATITIS B, CHRONIC; HUMANS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME;

HEPATITIS B VIRUS;

EID: 79851497065     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.546340     Document Type: Review

References (107)

1. LokAS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2
2. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005;25:472-89 (Pubitemid 40861895)
3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42
4. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003;23:47-58 (Pubitemid 36254662)
5. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335-52
6. McMahon BJ. The natural history of chronic hepatitis B virus infection. Semin Liver Dis 2004;24:S17-21
7. Brunetto MR A new role for an old marker, HBsAg. J Hepatol 2010;52:475-7
8. Nguyen T, Thompson AJV, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010;52:508-13
9. Jaroszewicz J, Serrano BC, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010;52:514-22
10. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002;35:1522-7
11. van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004;39:804-10 (Pubitemid 38337661)
12. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-7 (Pubitemid 26157437)
13. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001;34:306-13 (Pubitemid 32176454)
14. Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha interferon treated and untreated patients: a long term cohort study. J Hepatol 2002;36:263-70 (Pubitemid 34146434)
15. Lampertico P, Del Ninno E, Vigano M, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003;37:756-63 (Pubitemid 36397385)
16. Di Marco V, Lo Iacono O, Camma C, et al. The long term course of chronic hepatitis B. Hepatology 1999;30:257-64 (Pubitemid 29300594)
17. Bonino F, Brunetto MR Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview. J Hepatol 2003;39:S160-3 (Pubitemid 37222665)
18. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31
19. Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004;40:883-91 (Pubitemid 39288121)
20. van Zonneveld M, Flink HJ, Verhey E, et al. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. Aliment Pharmacol Ther 2005;21:1163-71 (Pubitemid 40646544)
21. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95 (Pubitemid 41007823)
22. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-9 (Pubitemid 40091801)
23. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008;135:459-67
24. Fried MW, Piratvisuth T, Lau GKK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008;47:428-34 (Pubitemid 351280710)
25. Hansen BE, Buster EH, Steyerberg EW, et al. Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment. J Med Virol 2010;82:1135-42
26. Flink HJ, van Zonneveld M, Hansen BE, et al. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006;101:297-303 (Pubitemid 43381671)
27. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-17 (Pubitemid 39296307)
28. Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alfa-2a. Gastroenterology 2009;136:2169-79
29. Marcellin P, Piratvisuth T, Brunetto M, et al. Increasing rates of HBsAg clearance and seroconversion in patients with HBeAg-negative disease treated with peginterferon alfa-2a ± lamivudine: results of 5-year post treatment follow up. J Hepatol 2009;50:S336
30. Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007;56:699-705 (Pubitemid 46662938)
31. Piccolo P, Lenci I, Demelia L, et al. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen negative chronic hepatitis B. Antivir Ther 2009;14:1165-74
32. Rijckborst V, Ter Borg MJ, Cakaloglu Y, et al. A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol 2010;105:1762-9
33. Gish RG, Lau DT, Schmid P, Perrillo R. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Am J Gastroenterol 2007;102:2718-23 (Pubitemid 350179320)
34. Lampertico P, Vigano M, Di Costanzo GG, et al. Extended (2 years) treatment with peginterferon alfa-2a [40kD] improves sustained response rates in genotype D patients with HBeAg negative chronic hepatitis B [abstract 98]. Presented at EASL, 14-18 April 2010, Vienna
35. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151-7
36. Marcellin P, Brunetto M, Bonino F, et al. In patients with HBeAg-negative chronic hepatitis B HBsAg serum levels early during treatment with peginterferon alfa-2a predict HBsAg clearance 4 years post-treatment. Hepatology 2008;48(Suppl 1):718A
37. Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010;52:454-61
38. Zoulim F. Combination ofnucleoside analogues in the treatment of hepatitis B chronic infection: lesson from experimental models. J Antimic Chemoter 2005;55:608-11 (Pubitemid 40691836)
39. Lai CL, Chien RN, Leung NW, et al. A one year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-8 (Pubitemid 28304879)
40. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63 (Pubitemid 29489740)
41. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999;29:889-96 (Pubitemid 29109606)
42. Keeffe E, Dieterich DT, Han SHB, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2006;2:87-106
43. Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32:847-51
44. Yuen MF, Sablon E, Hui CK, et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34:785-91 (Pubitemid 32928004)
45. Yuen MF, Fong DYT, Wong DK, et al. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007;46:1695-703
46. Santantonio T, Mazzola M, Iacovazzi T, et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000;32:300-6 (Pubitemid 30093910)
47. Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 2006;26:162-70 (Pubitemid 43668258)
48. Lampertico P, Vigano M, Manenti E, et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine resistant hepatitis B patients. Gastroenterology 2007;133:1445-51 (Pubitemid 350047463)
49. Iavarone M, Lampertico P, Vigano M, et al. Six years of on demand LAM+ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with HBeAg-negative cirrhosis. J Hepatol 2007;46:S189
50. Lai CL, Leung N, Teo EK, et al. A 1-year trial oftelbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-36 (Pubitemid 41096641)
51. Sung JJ, Lai JY, Zeuzem S, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008;48:728-35
52. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16 (Pubitemid 36245757)
53. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7 (Pubitemid 36245756)
54. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-55
55. Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004;126:81-90 (Pubitemid 38040726)
56. Peters MG, Hann Hw H, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91-101 (Pubitemid 38040727)
57. Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in preand post-liver transplantation patients. Hepatology 2003;38:1419-27 (Pubitemid 37466968)
58. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-51 (Pubitemid 44958517)
59. Hadziyannis S, Sevastianos V, Rapti IN, Tassopoulos NC. Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg negative chronic hepatitis B. Hepatology 2006;44:231A
60. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125:292-7 (Pubitemid 36929407)
61. Ha NB, Ha NB, Garcia RT, et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009;50:727-34
62. Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008;48:750-8
63. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-88 (Pubitemid 350294224)
64. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-95
65. Wang Y, Thongsawat S, Gane EJ, et al. Efficacy and safety outcomes after 4 years of telbivudine treatment in patients with chronic hepatitis B (CHB) [abstract 482]. 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009); October 30-November 1 2009, Boston
66. Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009;51:11-20
67. Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007;147:745-54 (Pubitemid 351664439)
68. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10 (Pubitemid 43357804)
69. Ren FY, Piao DM, Piao XX. A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B. World J Gastroenterol 2007;13:4264-7
70. Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133:1437-44 (Pubitemid 350029745)
71. Colonno RJ, Rose RE, Baldick CJ, et al. High barrier to resistance results in no emergence of entecavir resistance in nucleoside-naive subjects during the first two years of therapy. J Hepatology 2006;44(Suppl 2):S182
72. Shouval D, Lai CL, Chang TT, et al. Relapse of hepatitis B in HBeAg negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009;50:289-95
73. Chang TT, Lai CL, Yoon SK, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422-30
74. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-14
75. Leung N, Peng CY, Hann HW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009;49:72-9
76. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006;44:1656-65 (Pubitemid 44953670)
77. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-49 (Pubitemid 43816960)
78. Suzuki F, Toyoda J, Katano Y, et al. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J Gastrol Hepatol 2008;23:1320-6
79. Reijnders JG, Deterding K, Petersen J. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010;52:493-500
80. Shim JH, Suh DJ, Kim KM, et al. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology 2009;30:1064-71
81. Cho SW, Koh KH, Cheong JY, et al. Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance. J Viral Hepat 2010;17:171-7
82. Tong CW, Mullen JE, Wong T. Early hepatitis B virological rebound on entecavir through selection of lamivudine-associated mutations. J Antimicrob Chemother 2009;64:875-7
83. Kobashi H, Fujioka S, Kawaguchi M, et al. Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B. Hepatol Int 2009;3:403-10
84. Tenney DJ, Rose RE, Baldick CJ, et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. J Antimicrob Chemother 2007;51:902-11 (Pubitemid 46355274)
85. Lai CL, Shouval D, LokAS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20
86. Shouval D, Akarca US, Hatzis G, et al. Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (Study ETV-027). J Hepatol 2006;44(Suppl 2):S21-2
87. Chang TT, Liaw Y-F, Wu SS, et al. Long-term entecavir therapy results in reversal fibrosis/cirrhosis and continued histologic improvement in chronic hepatitis B patients. Hepatology 2010;52:886-93
88. Lampertico P, Vigano M, Facchetti F, et al. Entecavir for NUC-naive chronic hepatitis B patients in clinical practice: long-term effectiveness from a large multicenter cohort study in 376 patients [abstract 220]. 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009); October 30-November 1 2009, Boston
89. Baqai SF, Hana Yi D, Gish RG. Profound virologic response in chronic hepatitis B (CHB) patients treated with entecavir [abstract 476]. 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009); October 30-November 1 2009, Boston
90. SchiffE, Simsek H, Lee WM, et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008;103:2776-83
91. Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010;52:176-82
92. Liaw Y-F, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with evidence of hepatic decompensation [abstract 422]. 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009); October 30-November 1 2009, Boston
93. Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009;50:2001-6
94. Van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40:1421-5 (Pubitemid 39657017)
95. Heathcote E, Gane EJ, De Man RA, et al. Long term (4 Year) efficacy and safety of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-Positive patients (HBeAg+) with chronic hepatitis B (Study 103): preliminary Analysis [abstract 477]. 61th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2010); Boston
96. Marcellin P, Buti M, Krastev Z, et al. Continued efficacy and safety through 4 Years of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-negative patients with chronic hepatitis B (Study 102): preliminary Analysis [abstract 476]. 61th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2010); Boston
97. Gane EJ, Lee SS, Heathcote E, et al. Four years efficacy and safety of tenofovir disoproxil fumarate (TDF) in asians with HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB), preliminary analysis [abstract 481]. 61thAnnual Meeting of the American Association for the Study of Liver Diseases (AASLD 2010); Boston
98. Gordon SC, Marcellin P, Krastev Z, et al. 4 year efficacy of tenofovir disoproxil fumarate (TDF) in chronic hepatitis B patients with high viral load (HBV DNA ≥9 log10 copies/mL): preliminary analysis [abstract 137]. 61th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2010); Boston
99. Buti M, Hadziyannis S, Mathurin P, and others. Two years safety and efficacy of tenofovir disoproxil fumarate (TDF) in patients with HBV-induced cirrhosis [abstract 21]. 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009); 22-26 April 2009; Copenhagen, Denmark
100. Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2010: published online 27 October 2010, doi: 10.1002/hep.23952
101. van Bommel F, Zollner B, Sarrazin C. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006;44:318-25 (Pubitemid 44214870)
102. van Bommel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010;51:73-80
103. Berg T, Marcellin P, Zoulim F, et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic hepatitis B infection. Gastroenterology 2010;139:1207-17
104. Brunell MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005;41:1391-8 (Pubitemid 40770292)
105. Delaney WE, Yang H, Miller MD, et al. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother 2004;48:3702-10 (Pubitemid 39310516)
106. Liaw Y-F, Lee C-M, Akarca U, et al. Interim 48 week data of a phase 2, double-blind, randomized study comparing the safety of tenofovir disoproxil fumarate (TDF), emtricitabine plus TDF (Truvada, TVD) and entecavir (ETV) in subjects with decompensated chronic hepatitis B liver disease [abstract 122]. 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009); October 30-November 1 2009; Boston
107. Keeffe EB, Zeuzem S, KoffRS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5:890-7 (Pubitemid 47127032)